未知生产厂商
NeuVax is a HER2/neu peptide-based T-cell immunotherapy aimed at preventing disease recurrence and prolonging survival in cancer patients that have tumors which express the HER2/neu oncoprotein. To date, clinical study results have demonstrated that NeuVax significantly reduces the rate of cancer recurrence while showing minimal side effects. [Apthera Press release]
Investigated for use/treatment in prostate cancer and breast cancer.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
